Navigation Links
Aratana Therapeutics Provides 2013 Development Update
Date:12/23/2013

and AT-003, which are still in development; our inability to identify, license, develop and commercialize additional product candidates; our inability  to obtain regulatory approval for our existing or future product candidates;  the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; effects of competition; our failure to attract and keep senior management and key scientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; our lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an "emerging growth company," as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends.  These and other important factors discussed under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form
'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aratana to Participate in Leerink Swanns November Management Access Days
2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
10. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. Aratana Therapeutics names Wendy Yarno to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... Norgine B.V. today announced that ... bowel preparation, NER1006, presented at the 79 th ... (ACG), Philadelphia, PA , has met ... co-primary endpoint of cleansing success. The study demonstrated high ... in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... FRANKFURT , Deutschland, October 19, 2014 /PRNewswire/ ... echten CRT-Fallstudien gefragt. Das Problem dabei ... ihre Informationen mit der Kompetenz zu teilen. ... zusammenzustellen, und deshalb freuen wir uns umso mehr, ... Pharmafirmen gebeten, ihre Gepflogenheiten bei Kühlketten aufzuschreiben - ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... Arthritis Foundation,the leading health organization addressing the needs ... that Amgen and Wyeth,Pharmaceuticals, co-marketers of Enbrel (R) ... 2008 Arthritis Walk (R)., "The Arthritis Foundation ... funds to prevent, control and cure arthritis, the,nation,s ...
... in, Achieving Red Blood Cell Transfusion Independence, Hematologic Improvement ... ... the 49th American Society of Hematology (ASH) Meeting, ATLANTA, ... interim data from a Phase 2 clinical trial,evaluating three alternative ...
Cached Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 2MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 3MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 4MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 5MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule 6
(Date:10/20/2014)... It’s hard to imagine what it’s like to ... around the world, it’s a reality. And while new shoes ... forced to walk barefoot on rocky terrain or sewage-lined streets ... their friends. , Buckner International's Shoes for Orphan ... in October to encourage support for Air1 and while also ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... 20, 2014 Having been working in the ... knowledge of customer needs. According to James, one of the ... dazzling sequins, or with high-low skirts that add beauty to ... demand. Recently, LunaDress has unveiled its new selection of 2014 ... the company’s brand new items are available in over 20 ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... earlier U.S. study had different conclusion , THURSDAY, April ... being treated for erectile dysfunction finds an association between ... of the male hormone testosterone. , The study "sends ... director of sexual medicine at Alvarado Hospital in San ...
... plateaus, says CDC report , THURSDAY, April 15 (HealthDay ... food-related illnesses caused by several common bacteria, including the most ... a pathogen most often acquired from oysters which can cause ... rates of Salmonella infection have remained flat in recent years. ...
... conducted by a collaborative team led by researchers from the ... into the clinical outcome for some patients with a particularly ... a framework for development of targeted drug treatments. The ... in the journal Cancer Cell, used epigenomics to ...
... baby boomers will benefit from Social Security and Medicare at ... government-run programs will pay out more than they collect in ... from the University of California, Berkeley, concludes that younger Americans ... actually getting the better deal when the value of public ...
... ... Solution Enhances Tracking and Management of Items, Assets, and Containers, , ... (PRWEB) April 15, 2010 -- ... Frequency Identification (RFID) solutions, today announced that they are partnering to offer the industry,s ...
... ... to announce that Maureen Hanrahan has joined the company as a senior consultant specializing ... Medicaid and SCHIP. , ... (PRWEB) April 15, 2010 -- ArpegioHealth is pleased to announce that ...
Cached Medicine News:Health News:Do Statins Lower Male Sex Drive? 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 2Health News: E. coli Declines, but Other Foodborne Illnesses a Worry 3Health News:USC researchers discover new molecular subtype of brain cancer 2Health News:For post-boomers, public education worth more than Social Security and Medicare 2Health News:For post-boomers, public education worth more than Social Security and Medicare 3Health News:Savi and ODIN to Deliver Industry's Most Comprehensive RFID Software Platform 2Health News:Savi and ODIN to Deliver Industry's Most Comprehensive RFID Software Platform 3Health News:Hanrahan Joins ArpegioHealth Consulting Firm 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... Ang II is a helpful ... effect and efficiency of a ... enzyme inhibitors (ACE Inhibitors) or ... well as for the efficiency ...
Medicine Products: